GlassScriptPhysician profile
Sarah S Pinney
NPI 1619261443
$3,163.36
in general payments reported to CMS, 2019-2025
25 companies · $758 in 2025
The $758 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $281 · 2021: $444 · 2022: $261 · 2023: $450 · 2024: $488 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.20 |
| Education | $166.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $624.46 | 2024-2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $620.66 | 2019-2025 | |
| Janssen Biotech, INC. | $474.37 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $457.99 | 2019-2025 | Rinvoq |
| Lilly USA, LLC | $141.56 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $107.20 | 2019-2023 | Absorica Ld, Winlevi, Ilumya |
| Regeneron Healthcare Solutions, INC. | $90.19 | 2020-2021 | |
| Pfizer INC. | $87.22 | 2019-2025 | |
| Amgen INC. | $82.27 | 2020-2025 | Otezla, Otezla |
| Genzyme Corporation | $78.70 | 2023-2024 | |
| Ucb, INC. | $64.11 | 2019-2025 | Bimzelx |
| Celgene Corporation | $45.59 | 2019 | |
| Galderma Laboratories, L.P. | $39.44 | 2023-2025 | |
| Leo Pharma INC. | $37.02 | 2019-2020 | |
| Epi Health, LLC | $28.44 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $24.85 | 2021 | |
| Almirall LLC | $23.68 | 2019 | |
| Merz North America, INC. | $19.94 | 2022 | |
| Genentech USA, INC. | $19.54 | 2024 | Erivedge |
| Dermira, INC. | $19.28 | 2019 | |
| Dusa Pharmaceuticals, INC. | $18.42 | 2019 | |
| Mayne Pharma Commercial LLC | $16.59 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.83 | 2021 | |
| Vyne Pharmaceuticals INC. | $14.01 | 2020 | |
| Incyte Corporation | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Pinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.